Advertisement
Advertisement
HALO
Halozyme Therapeutics, Inc.
65.40
USDSponsored
+0.70
+1.09%
Apr 01, 15:59 UTC -4
Closed
Pre-Market
63.97
-1.44
-2.19%
HALO Earnings Reports
Positive Surprise Ratio
HALO beat 30 of 41 last estimates.
73%
Next Report
Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$364.76M
/$1.55
Implied change from Q4 25 (Revenue/ EPS)
-19.26%
/-745.83%
Implied change from Q1 25 (Revenue/ EPS)
+37.72%
/+39.64%
Halozyme Therapeutics, Inc. earnings per share and revenue
On Feb 17, 2026, HALO reported earnings of -0.24 USD per share (EPS) for Q4 25, missing the estimate of 2.24 USD, resulting in a -110.70% surprise. Revenue reached 451.77 million, compared to an expected 446.74 million, with a 1.13% difference. The market reacted with a -9.01% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of 1.55 USD, with revenue projected to reach 364.76 million USD, implying an decrease of -745.83% EPS, and decrease of -19.26% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Palvella Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.92
Actual
-$1.08
Surprise
-16.19%
Bicara Therapeutics Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.68
Actual
-$0.68
Surprise
+0.66%
Neumora Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.33
Actual
-$0.35
Surprise
-5.39%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.17
Surprise
+7.41%
Sangamo Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-14.38%
RenovoRx, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.08
Surprise
+1.96%
INmune Bio Inc. Common stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.26
Actual
-$0.18
Surprise
+32.13%
PDS Biotechnology Corporation Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.14
Surprise
+27.76%
VolitionRX Limited Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.05
Surprise
-17.65%
Lantern Pharma Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.36
Surprise
+23.27%
FAQ
What were Halozyme Therapeutics, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Halozyme Therapeutics, Inc. reported EPS of -$0.24, missing estimates by -110.7%, and revenue of $451.77M, 1.13% above expectations.
How did the market react to Halozyme Therapeutics, Inc.'s Q4 2025 earnings?
The stock price moved down -9.01%, changed from $80.48 before the earnings release to $73.23 the day after.
When is Halozyme Therapeutics, Inc. expected to report next?
The next earning report is scheduled for May 04, 2026.
What are the forecasts for Halozyme Therapeutics, Inc.'s next earnings report?
Based on --
analysts, Halozyme Therapeutics, Inc. is expected to report EPS of $1.55 and revenue of $364.76M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement